Search Results - "BAEKELANDT, Mark M. O"

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer

    Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer by LHOMME, Catherine, JOLY, Florence, JONES, Gary J, DUGAN, Margaret H, WALKER, Joan L, LISSONI, Andrea A, NICOLETTO, Maria O, MANIKHAS, Gregory M, BAEKELANDT, Mark M. O, GORDON, Alan N, FRACASSO, Paula M, MIETLOWSKI, William L

    Published in Journal of clinical oncology (01-06-2008)
    “…To compare the safety and efficacy of carboplatin and paclitaxel administered with or without the multidrug resistance modulator valspodar (PSC 833) in…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma

    Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma by Wang, Yun, Kringen, Pedro, Kristensen, Gunnar B., Holm, Ruth, Baekelandt, Mark M.O., Olivier, Magali, Skomedal, Hanne, Hainaut, Pierre, Tropé, Claes G., Abeler, Vera M., Nesland, Jahn M., Børresen-Dale, Anne-Lise, Helland, Åslaug

    Published in Human mutation (01-07-2004)
    “…This study was conducted to evaluate the frequency and prognostic impact of TP53 alterations stratified for the TP53 codon 72 polymorphism (c.215G>C,…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: